Klin Padiatr 2019; 231(03): 162-163
DOI: 10.1055/s-0039-1687147
Abstracts
Georg Thieme Verlag KG Stuttgart · New York

Deciphering the role of lncRNAs in pediatric AML

R Bhayadia
1   Martin-Luther-University Halle-Wittenberg; Germany
,
M Ng
1   Martin-Luther-University Halle-Wittenberg; Germany
,
H Dirk
1   Martin-Luther-University Halle-Wittenberg; Germany
,
JH Klusmann
1   Martin-Luther-University Halle-Wittenberg; Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
20 May 2019 (online)

 

Acute myeloid leukemia (AML) is a hematopoietic malignancy defined by genetic (and epigenetic) alterations in hematopoietic stem or progenitor cells. The emerging picture portrays a chromatin and transcriptional landscape that precisely controlled in four dimensions (space, time, cell type, developmental status) by a range of regulatory long non-coding RNAs (lncRNAs). Previously, we generated a gene expression atlas uncovering prognostically relevant lncRNA signatures shared between various AML sub-types and healthy hematopoietic stem cells. To elucidate the relevance of lncRNA candidates in leukemogenesis we performed an in vivo CRISPRi-based dropout screen. We targeted leukemic cell lines with various mutational sub-types and patient derived xenografts with stable expression of dCas9-KRAB. In our in vivo experimental design, firstly, we determined frequency of leukemia-initiating cells using a barcode approach. Thereafter we subjected our lncRNA candidate sub-libraries for screening potential candidates. Dropout candidates of the screening are further being validated via proliferation assays and qPCR.